Articles

Bilateral implantation of the Acri.LISA 366D distance-dominant bifocal intraocular lens provides a satisfactory full range of vision.

Conformal fractionated radiotherapy should be the first choice of treatment for optic nerve sheath meningiomas.

Transvitreal optic neurotomy (TON) improves the visual acuity and visual fields in patients with nonarteritic anterior ischemic optic neuropathy (NAION) of recent onset.

The final report of the Optic Neuritis Treatment Trial (ONTT) showed that the long-term visual outcome is favorable for patients with unilateral acute optic neuritis even in the presence of multiple sclerosis.

CCI unrelated to endophthalmitis risk. US surgeons not following recommendations of European endophthalmitis study. NSAID use questioned, and much more.

All the news from the meeting of the American Academy of Ophthalmology, held November 10–13 2007 in New Orleans, Louisiana.

Topical nonsteroidal anti-inflammatory drugs (NSAIDs) are often used off-label for multiple purposes in cataract surgery, but such treatment is often being administered with limited supporting evidence and carries a high cost along with potential risks.

Daily audio coverage of the 2007 AAO annual meeting.

When thinking about administering medications intracamerally during cataract surgery, it is important to consider whether their potential benefits are worth the risk.

Concomitant delivery of focal radiotherapy and bevacizumab (Avastin, Genentech) showed promise in a small multicenter feasibility study of patients with neovascular age-related macular degeneration.

According to the results of an online survey conducted by the ASCRS Cataract Clinical Committee, the results of the ESCRS study of endophthalmitis prophylaxis do not appear to have had a significant impact on the practices of US cataract surgeons.

Clear corneal incision (CCI) is not a risk factor for post-cataract surgery endophthalmitis.

New crystalens looking good. Practical tips for ocular surface disease in glaucoma patients. Ellex announces results for retina regeneration, and much more.

Results of 10-year follow-up of patients with high myopia who underwent LASIK indicate that the procedure is safe and effective over the long term.

The use of medical adjuvant therapy for macular holes during vitreous surgery seems to be decreasing in macular hole surgery, said Alain Gaudric, MD, of Lariboisière Hospital, Paris.

New roles for the femtosecond discussed. Subretinal implant disappoints. Genentech defends its actions relating to Avastin decision. Glaucoma pipeline looks very healthy, and much more.

A fourth-generation version of an accommodating IOL (HD-100 crystalens, eyeonics) provides excellent uncorrected visual acuity (UCVA) at all distances without degrading contrast acuity, according to the results of an FDA multicenter clinical trial.

Intravitreal therapy for venous occlusive disease is promising in the short term, however, multiple injections are needed, dosing schedules are presently unclear, and rebound has to be evaluated.

Posterior continuous curvilinear capsulorhexis (PCCC) with optic capture of a posterior chamber IOL is a safe and effective technique to afford stable IOL fixation and maintain visual axis clarity after cataract surgery in pediatric eyes.

The condition of the ocular surface influences the outcome of cataract and refractive surgery and can also affect recovery following some surgical procedures.

An analysis of visual outcomes in a contemporary series of cataract surgery eyes that underwent pars plana vitrectomy (PPV) for retained lens material indicates these complicated cases tend to do well.

The surgical approach chosen by Borja Corcóstegui, MD, to repair vitreous detachments is driven by the classification of the detachment.

Initial experience with intraoperative use of a wavefront analyzer (WaveTec Visions Systems) suggests that it may be a very useful tool for achieving increased accuracy and efficiency in astigmatism correction.

Off-label use of intravitreal drugs may have a promising future in the treatment of patients with diabetic retinopathy, but currently the dosing of these drugs is suboptimal.

Rutledge Ellis-Behnke, PhD, a research scientist in the department of brain and cognitive sciences, Massachusetts Institute of Technology (MIT), Boston, describes his work as reconnecting disconnected parts of the brain. He has done just that by using nanotechnology restore visual function in a damaged area of the brain in rodents.

Levofloxacin ophthalmic solution 1.5% (Iquix) has been introduced for the treatment of corneal ulcers. It is the only newer-generation fluoroquinolone approved by the FDA for this indication.

The initial clinical results were announced of a continuous study for non-thermal Retina Regeneration Therapy (Ellex 2RT, Ellex Medical Lasers Ltd.). The results showed the therapy's potential to make improvements in and stabilize visual acuity, as well as reduce retinal edema in patients with diabetic maculopathy and macular edema without causing any damage to the photoreceptors.

The drug development pipeline is bursting with new pharmaceutical products that may one day be useful in glaucoma therapy.

Studies provide guidance on MMC use. Going back to the surface with refractive surgery. AMO unveils iLASIK vision correction, and much more.

Keratoectasia can develop after surface ablation in eyes with forme fruste keratoconus (FFKC), and there do not appear to be any identifiable features as protecting against that event.